Building Resilience Against Artificial Intelligence–Enabled Biological Threats

Why It Matters

AI accelerates both biotech innovation and the potential for misuse, making coordinated resilience essential for national security and public health.

Key Takeaways

• Workshop gathered 22 cross‑sector experts on AI‑bio risks
• Developed mitigation portfolio covering technical, policy, operational layers
• Identified implementation dependencies and potential failure modes
• Assigned stakeholder responsibilities for near‑term actions
• Roadmaps target both immediate and long‑term biosecurity resilience

Pulse Analysis

Artificial intelligence is reshaping the life‑sciences landscape, enabling rapid drug discovery, gene‑editing, and synthetic biology breakthroughs. This acceleration, however, creates a dual‑use dilemma: the same tools that accelerate cures can also streamline the design of harmful pathogens. As AI models become more capable and accessible, the biosecurity community faces a widening gap between innovation and oversight, prompting urgent calls for governance frameworks that balance scientific progress with safety.

The RAND Center's "From Risk to Resilience" workshop brought together a uniquely interdisciplinary cohort—AI engineers, biotech CEOs, ethicists, and security analysts—to confront this gap head‑on. By segmenting the AI‑bio risk chain into model capabilities, supply‑chain vulnerabilities, and governance blind spots, participants crafted a suite of mitigations that span technical safeguards, policy reforms, and operational best practices. The resulting roadmap outlines short‑term pilots, such as secure model‑sharing protocols, alongside longer‑term institutional reforms, including cross‑agency coordination mechanisms and industry standards for AI‑driven bio‑experiments.

For policymakers and industry leaders, the workshop’s outputs signal a shift from abstract threat assessments to actionable resilience planning. Implementing the proposed interventions can reduce the likelihood of accidental releases and deter malicious actors seeking to weaponize AI‑enhanced biology. Moreover, the emphasis on stakeholder responsibility encourages a shared security culture, where private firms, academic labs, and government agencies co‑develop safeguards. As AI continues to embed itself in biological research, these collaborative mitigation strategies will be pivotal in preserving public health while sustaining innovation.